Sarepta (SRPT) Appoints Henri Termeer As Advisor To The Company

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced Henri Termeer, industry leader and former CEO of Genzyme, will be a key advisor to the Company.

"I am honored to have Henri Termeer, a pioneer of rare disease companies, serve as an advisor as we seek FDA approval for our lead product candidate and build a rare disease organization," said Edward Kaye, M.D., Sarepta's interim chief executive officer and chief medical officer.